Previous 10 | Next 10 |
The Ukraine-Russia crisis continues heating up, which has profoundly impacted everything, including penny stocks. Today more updates on Russia and Ukraine surfaced, citing a “pro-Russian” attack on a border village. Meanwhile, Russian-controlled media outlet RIA said that Ukra...
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids Study expected to begin enrolling patients in the first half of 2022 Hemorrhoids affect approximately 5% of the US population,...
Citius Pharmaceuticals press release (NASDAQ:CTXR): FQ1 GAAP EPS of -$0.06 in-line. Cash and cash equivalents of $65.4M. "We anticipate 2022 will be a year of important catalysts for Citius. The timeline for the I/ONTAK program remains on track, with topline results anticipated in the first h...
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business Update Strong balance sheet with $65.4 million in cash and cash equivalents as of December 31, 2021 and no debt Topline results of Pivotal Phase 3 trial in cancer immunothe...
Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences H.C. Wainwright BioConnect 2022 Conference January 10-13, 2022 Biotech Showcase Virtual Conference January 17-19, 2022 PR Newswire CRANFORD, N.J. , Jan. 4, 2022 /PRNewswire/ -...
Citius Pharmaceuticals (NASDAQ:CTXR): FY GAAP EPS of -$0.23. As of September 30, 2021, the Company had $70.1 million in cash and cash equivalents. During the fiscal year ended September 30, 2021, the Company received net proceeds of $120.6 million from financing activities. Shares +0.59%. Pre...
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update $70.1 million in cash and cash equivalents as of September 30, 2021 to advance pipeline Completed treatment phase of Pivotal Phase 3 trial in cancer immunotherapy I/ONTA...
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma Topline study results expected in the first half of 2022 Biologics License Application (BLA) filing anticipated in the ...
Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls Seasoned regulatory and manufacturing executive with 20 approved market applications in the US and Europe and 50 regulator...
Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients KOL Event will be held Thursday, November 11th at 11:30 a.m. ET PR Newswire CRANFORD, N.J. , Oct. 25, 2021 /PRNewswire/ -- ...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...